News | EP Lab | May 12, 2021

Pulsed Electric Field Focal Ablation Catheter From Galaxy Medical and Japan Life Will Seek FDA Clearance 

Companies create U.S. distribution agreement 

EP lab at the University of Colorado

May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy Centauri Pulsed Electric Field (PEF) System.  Under the terms of the agreement, Galaxy will pursue U.S. regulatory approval for Alpha1 in support of eventual commercialization of the CENTAURI PEF System.

PEF is a new type of ablation technology for use in electrophysiology (EP) procedures. It is also called electroporation, because the field it creates opens pores in the cell walls, leading to cell death. The goal is deliver more controlled lesions with less collateral damage. 

The Alpha1 was engineered to handle the increased electrical demands associated with PEF therapy, without sacrificing the handling, flexibility or feel that physicians expect. It has an 8 French outer diameter, 4 mm platinum ablation tip and a full 180 degrees of bilateral deflection. It was optimized to work with the two major inventions that are unique to the Centauri PEF System:

The proprietary Wave1 waveform reduces muscle stimulation and eliminates microbubbles seen with other PEF ablation products that can cause strokes.
The proprietary Centauri Connect box allows physicians to perform PEF ablation procedures with focal catheters and mapping systems they currently use for routine radiofrequency procedures, saving training time, workflow adjustments and cost.

"We have long sought to bring our outstanding ablation technologies to the U.S. market. In this partnership with Galaxy and their expertise in PEF technology, we aim to be at the forefront of innovation in ablation, bringing new therapies to the millions of people worldwide who suffer from cardiac arrhythmias," said Kei Suzuki, CEO of Japan Lifeline.

"We are thrilled to partner with Japan Lifeline on the first focal PEF system. Over the last several months, Galaxy and Japan Lifeline engineers have collaborated to design Alpha1, allowing PEF energy to target a wide array of arrhythmias," said Jonathan Waldstreicher, M.D., CEO of Galaxy Medical. "We chose to start with a focal approach because 87% of catheter ablations worldwide are performed in this manner, aligning with our mission of democratizing the use of PEF energy.  As we embark on clinical trials with the system, we hope to demonstrate enhanced safety and efficacy as compared to today's standard of care."

Centauri and Alpha1 are investigational devices and not commercially available.

For more information: www.galaxymed.com, www.japanlifeline.com

 

Related Pulsed Electric Field Ablation Technology Content:

Pulsed Field Ablation Successfully Treats Atrial Fibrillation

What is New in Electrophysiology Technologies

Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation

VIDEO: Current State of Atrial Fibrillation Ablation Technologies

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

First Patients Treated with Galaxy Medical Centauri Pulsed Electric Field Cardiac Ablation System

Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy

Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations
 

 

Related Content

News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
News | Ablation Systems

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an ...

Home May 14, 2019
Home
News | Ablation Systems

May 13, 2019 — Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands ...

Home May 13, 2019
Home
Subscribe Now